At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
Desvenlafaxine Succinate Sustained-Release (DVS SR) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Aug 1, 2008·Updated Jun 2, 2010
In Brief
A Phase 1 clinical trial evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) and Venlafaxine Extended Release (VEN ER) for Healthy. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedAug 2008
Primary CompletionAug 2008
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartJun 1, 2008
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.9 years ago
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR)drug
Venlafaxine Extended Release (VEN ER)drug